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In this brief abbreviated review of regulatory issues regarding the development of drugs and or devices
for the treatment of osteoarthritis (OA), the steps that are expected by both the Food and Drug
Administration (FDA) and the European Medicines Agency (EMA) are discussed.
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
In both theUS and in Europe, drugs are approved on accumulated
clinical and non clinical data which demonstrates the potential
beneﬁts and risk of harm in the appropriate patients studied. The
beneﬁt of therapies have to in general, deﬁne how a patient feels,
functions or survives. The development of new therapeutics, either
drugs and devices, for the treatment of osteoarthritis (OA) for
improvement in signs and symptoms such as pain or decreased
function as well as potentially those treatments which will alter the
natural history of the disease as determined by altering structural
progression, requires a development company to follow guidances
developed to provide a roadmap on best practices considered at the
timeby the regulatoryagencies inboth theUSand inEurope1,2. Table I
outlines the development steps followed by a sponsor developing a
drug or biologic therapy while interacting with the regulatory
agencies which are expected to assure adequate data collection for
justifying approval. Table II outlines the steps that a development
company would follow if developing a device within the US.
Device development in the US is handled by a branch of the Food
and Drug Administration (FDA), the Center for Device and Radio-
logic Health (CDRH) and is governed by different requirements than
drugs or biologic therapies. If a device is being developed which isternational. Published by Elsevier Lhighly similar to one that already has been on the market then the
sponsor of that development program can pursue a “510k” proce-
dure which leads, if successful, to the FDA “clearing” the use of the
new device. Alternatively, approval of a new device may require a
Pre Market Application (PMA) which is a dossier not dissimilar
from a New Drug Application (NDA) or Biologic License Application
(BLA) reviewed within the Center for Drug Evaluation and Research
(CDER).
The process is quite different in the European Community and is
mostly dependent on obtaining a CE mark for use across the Eu-
ropean Economic Community. The CE mark represents the manu-
facturer's declaration that the product meets the requirements of
the applicable European Community directives governing the
particular device. This is done thru a different group than European
Medicines Agency (EMA).
Both the FDA and EMA have been considering the approach to
OA for years and have determined that drugs which are developed
to alter structural progression will likely have to concomitantly
treat the signs and symptoms of OA. However, the EMA has stated
that it is possible that structure modiﬁcation might at a later date
provide symptomatic beneﬁts, but this has yet to be proven2. In
regulatory terms, that means until proven otherwise, a drug pro-
posed to alter the structural progression of OA will need to
concomitantly improve a patient's signs and symptoms. Further-
more, drugs or devices that might be structure modifying, will need
to provide evidence over at least 1 year if not longer, to demonstratetd. All rights reserved.
Table I
What steps are necessary for drug or biological therapy approvals?
Non clinical safety
Deﬁne dose exposures as related to risk, maximally tolerated dose, no effect level in two species.
Timed exposure for drugs for chronic therapy to provide “cover” for ﬁrst in human studies as well as longer term exposure. Study reports have to be signed to be
considered complete.
Pre IND meeting
Held once enough non clinical data is accumulated to obtain a regulatory picture of what will be generally necessary for the indication sought.
Clinical studies
Phase I
Single ascending dose studies mostly in normal human volunteers but depending on the mechanism of action (MOA) of the therapy, if there is risk, this might be done in
the appropriate patient.
Multiple ascending dose studies sometimes done in normal human volunteers but sometimes performed in patients.
Phase II
Studies are performed in selected patients to deﬁne dose, dosing schedule as well as potentially minimally effective dose.
Assessments of primary and other outcomes.
Differences in formulations might be tested; however, if telescoping development time is important, then all such trials have to be considered adequate and well
controlled, using commercial material, following good laboratory practice, good manufacturing practice and good clinical practice guidelines.
End of Phase II meeting
To determine way forward including number of patients that will need to be exposed to any dose and dose formulation as well as how patients many need to receive the
commercial formulation, dose and dosing schedule.
What primary outcomes will allow which indications to be awarded.
A preliminary discussion of the planned statistical analysis plans and the analysis of measuring an effect size which will be clinically meaningful.
Phase III
Once an optimal dose or doses is (are) determined, then pivotal trials for regulatory approval can be performed.
Usually of larger numbers of patients with a broader demographic footprint is recruited than earlier trials. Inclusion and exclusion criteria are considered.
Multicenter trials are required with a representative demographic of patients which reﬂects the demographic of patients in the US.
Enough patients need to be studied, with adequate and well controlled trials to allow for a clinically relevant beneﬁt as opposed to risk due to emerging adverse events
assessment to be concluded.
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developed to treat the signs and symptoms of OA of a speciﬁc joint
typically require randomized controlled trials lasting 12 weeks
with a minimum number of patients studied for up to 1 year, since
OA is a considered a chronic process. This report will not outline the
requirements for drugs or devices developed to treat acute pain of
OA.
Overall exposure: number of patients required
The number of patients required to be exposed to a speciﬁc drug
or biologic therapeutic is governed mostly by international agree-
ments. The International Conference on Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for Human Use
(ICH), requires 1500 patients exposed at any dose, 300e600 pa-
tients exposed to the proposed therapeutic dose for three to
6 months, and at least 100 patients exposed for at least 1 year3.
What would a typical development program look like?
A typical development program will need to have deﬁned ﬁrst,
in non clinical studies in two species, the maximal tolerated dose in
the animal as well as a drug serum level where no safety signals are
noted or the no affect level is deﬁned. Then, clinical studies will
need to deﬁne the minimally effective dose, as well as the no affect
level of dose, thus the highest dose tolerated but without safetyTable II
What steps are required for device approvals
Pre Investigational Device Exemption (pre IDE) meeting
At this meeting, clarity is achieved as to whether the sponsor may pursue a “510K” ap
Furthermore, the number of patients to be studied with the new device is deﬁned.
Safety is a much more important issue within CDRH and efﬁcacy may take a back seat
beneﬁt especially if there are unique safety signals observed with the new device.
PMA meeting
If a PMA is required, then typically substantive clinical trials may be required. The guid
path forward with modiﬁcations as determined by the review division within CDRH
PMA
Submission of the PMA.signals in patients. Furthermore, the optimal dose level and dose
duration so that timing of dose is also identiﬁed. Once that is done,
for the development of a new molecular or chemical entity,
whether it be a small molecule or a biologic therapy, the sponsor
likely needs to succeed with two replicate and adequate and well
controlled randomized controlled trials (not necessarily identical
trials).
Since OA is a chronic process and although intermittent therapy
might be used to alleviate symptoms, the standard design should
last for at least 12 weeks at which time the primary outcome is
considered. These patients should also be subsequently enrolled
into an extension trial for an understanding of safety with longer
term exposure to provide for at least 100 patients exposed for 1
year, as noted previously, although the exact number should be
deﬁned by the review divisions in the FDA or the scientiﬁc advice
committee within EMA depending on the mode of action of the
purported therapy1,2. This report is part of a larger number of pa-
pers discussing various studies to be considered for different forms
of OA, and there are separate papers on speciﬁc trial designs and
statistical analysis plans to be considered.
What about devices?
In the US, devices are developed and governed by the same OA
FDA guidance as are drugs and biologic therapies; whereas, in
Europe, devices are predominantly governed by uniformproach (see text) or has to perform a full development program leading to a PMA.
depending on the therapy. However, it is always a useful measure to deﬁne the
ance document for the Development of Drugs in the Treatment of OA deﬁnes the
.
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US, devices are required to be proven safe when used as thera-
peutics and are cleared by the FDA if they are proven similar to
other devices, or they can be approved for use by submission of a
PMA for review The evidence to support a PMA for the treatment of
OA is similar to the requirements that the CDER at the FDA requires.
If a new therapy is approved, what are the present indications
for OA?
In the US, there are two different possible indications awarded
at approval for a new therapy for signs or symptoms of OA. The ﬁrst
is to be awarded an indication for the treatment of the signs and
symptoms of OA. This threshold for approval requires the sponsor
to demonstrate that the therapy is statistically better than placebo
with an effect size that is clinically relevant in terms of pain, some
functional assessment (typically Western Ontario and McMaster
Universities Osteoarthritis Index (WOMAC) function) and some
form of question to determine the patient global response to the
therapy. The patient global question usually encompasses both a
sense of beneﬁt and presence of adverse events noted by the pa-
tient while being treated with the new putative therapy1,2. How-
ever, in the US, the other possible indication is the treatment of the
“pain of OA of the knee” or whatever speciﬁc joint has been studied.
This would require clinical studies designed to prove that the study
drug was better than placebo statistically and the effect size was
also clinically relevant in terms of pain relief with both a functional
outcome and a patient global question as secondary outcomes
which do not need to be statistically signiﬁcantly better than pla-
cebo, but also cannot worsen1,2,4. In Europe, EMA likely will require
an active comparator as well. This serves two purposes. By using an
approved drug as an active comparator provides a positive control
to allow more conﬁdence in the completion of an adequate and
well controlled trial with noted success of the active comparator.
The second issue, is that the presence of an active comparator in the
same trial, provides for European regulators a sense of comparative
effectiveness comparing the study drug to the effect of a known
active therapeutic. As of yet, this is not required in the US.
If a topical drug is being developed, then the overall approach is
similar; however, the speciﬁc joint treated is the one the product is
labeled for and is for either the treatment of the signs and symp-
toms of OA or the treatment of pain of OA, (e.g., treatment of OA of
the knee, or the treatment of pain of OA of the knee). Replicate trials
are still required and systemic exposure is also important to deﬁne.
Depending on the efﬁciency of absorption of the product as well as
the bioavailability there may be more studies necessary to further
understand the safety issues when the product is used.
Both in the US and in Europe, a sponsor could prove that the
study drug is better than placebo in at least three different sites (for
a topical to obtain the pain of OA or the treatment of OA and not of a
speciﬁc joint), or in the case of a systemic therapy, achieving the
broader indication for the treatment of musculoskeletal pain, the
sponsor would need to succeed in studies of at least threemodels of
musculoskeletal pain. For example, duloxetene was awarded such
an indication after successfully demonstrating beneﬁt in the
treatment of OA, low back pain, and ﬁbromyalgia4,5.
Unique aspects of a structure modifying development
program
To obtain a structure modifying indication, thus proving that the
therapy slows, retards, or stops OA progression, the study should belong enough to allow for a clinically relevant change to be
measurable. Presently, joint space narrowing measurement by X-
ray is the anchor evidence, but much data has been accumulated to
suggest that magnetic resonance imaging (MRI) is now a generally
accepted technique6. Both the FDA and EMA acknowledge this;
however, there has been little data presented to either regulatory
body in a drug development program which has succeeded with
either an MRI outcome or an X-ray outcome. Recommendations
from OMERACT and OARSI have presented supporting evidence for
this to the FDA6.Is there are way to enhance likelihood of success?
An enrichment guidance was developed by the FDA to deﬁne
the process of increasing success in carrying out clinical trials
which will be used for approval in indications such as OA which
are characterized by signiﬁcant patient heterogeneity7. This al-
lows recruitment of patients with manifestations of OA which
are more likely to demonstrate responsiveness in such clinical
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